MedRhythms announces the advancement of its pipeline of neurologic rehabilitation products in multiple sclerosis (MS) and Parkinson’s disease (PD).
As part of this effort, MedRhythms has established MS and PD Scientific Advisory Boards that will provide guidance related to the company’s clinical and research activities in these disease states.
Additionally, MR-004, the Company’s pipeline product for walking rehabilitation in MS, will be studied at Cleveland Clinic in a pilot-scale randomized controlled trial to evaluate its safety and efficacy. This trial is made possible by a grant from the Consortium of Multiple Sclerosis Centers (CMSC), it notes in a media release.
MedRhythms Dr Francois Bethoux and Dr John DeLuca to the MS Scientific Advisory Board. Bethoux is the Director of Rehabilitation Services at the Mellen Center for Multiple Sclerosis at Cleveland Clinic as well as the Chair of the Research Interest Group on Symptom Management of the Consortium of Multiple Sclerosis Centers. DeLuca is the Senior Vice President for Research and Training at the Kessler Foundation and a professor at Rutgers New Jersey Medical School in the Physical Medicine & Rehabilitation Department and the Neurology Department.
Bastiaan Bloem, MD, PhD, Ray Dorsey, MD, MBA, and Alexander Pantelyat, MD, joins the PD Scientific Advisory Board as first advisors. Bloem is the Co-Director for Parkinson’s Net, Scientific Advisor of the Michael J. Fox Foundation, and an author of 550 publications. Dorsey is the Director of the Center for Health Technology at the University of Rochester and the Editor-in-Chief of Digital Biomarkers Journal. Pantelyat is the Director of the Atypical Parkinson’s program at Johns Hopkins and the Director of the Johns Hopkins Center for Music and Medicine.
“We are excited to advance the pipeline of products by adding these world-renowned researchers and clinicians to our MS and PD Scientific Advisory Boards,” Brian Harris, Co-Founder and CEO of MedRhythms, says in the release.
The study that’s researching the outcomes of MR-004 on subjects with MS will be initiated in early 2020 at Cleveland Clinic. Bethoux will serve as the principal investigator.
“I’ve conducted many trials on interventions to improve walking in those living with MS, including the compelling impacts of rhythmic cueing in this population,” Bethoux states.
“I look forward to undertaking the role of principal investigator in this study and to learn more about this investigational therapy and its potential impact on mobility and quality of life in patients with MS.”
[Source(s): MedRhythms, PR Newswire]